BamSEC and AlphaSense Join Forces
Learn More

Cartesian Therapeutics Inc. – Material Contracts

NASDAQ: RNAC    
Share price (3/26/26): $6.08    
Market cap (3/26/26): $161 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.22
from 10-K 7 pages Material contract
12/34/56
EX-10.1
from 10-Q 5 pages Fourth Amendment to Lease Agreement
12/34/56
EX-10.2
from 10-Q 15 pages Separation Agreement and Release
12/34/56
EX-10.1
from 10-Q 16 pages Third Amendment to Lease Agreement
12/34/56
EX-10.5
from 10-K 4 pages Cartesian Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.3
from 10-K 32 pages Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan
12/34/56
EX-10.1
from 10-Q 7 pages Second Amendment to Lease Agreement
12/34/56
EX-10.6
from S-1 4 pages Cartesian Therapeutics, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.3
from S-1 31 pages Cartesian Therapeutics, Inc. Amended and Restated 2018 Employment Inducement Incentive Award Plan
12/34/56
EX-10.1
from S-1 33 pages Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan
12/34/56
EX-10.2
from 8-K 21 pages Form of Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 69 pages Securities Purchase Agreement
12/34/56
EX-10.3(B)
from 10-Q 7 pages First Amendment to Lease Agreement
12/34/56
EX-10.2
from 8-K 21 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 20 pages Employment Agreement
12/34/56
EX-10.21
from 10-K 93 pages License and Development Agreement Dated January 8, 2023 by and Between Selecta Biosciences, Inc. and Audentes Therapeutics, Inc
12/34/56
EX-10.17
from 10-K 6 pages Non-Exclusive Patent License Agreement
12/34/56
EX-10.16
from 10-K 24 pages Public Health Service Patent License-Non-Exclusive
12/34/56
EX-10.15(B)
from 10-K 11 pages Amendment No. 1 to License and Development Agreement
12/34/56
EX-10.12
from 10-K 56 pages Lease Agreement
12/34/56